Shots:

• Ionis to receive a $200M up front, $485M in development and approval milestones in addition to $2.9B in sales-related milestones along with royalties. The transaction is expected to close at an end of 2021
• AstraZeneca to get an exclusive license for eplontersen outside the US & will lead the commercial supply. Ionis will be responsible to conduct the P-III clinical trials in patients with hATTR with polyneuropathy and cardiomyopathy & will manufacture and supply eplontersen for the ongoing clinical trials
• Additionally, both companies will be responsible to share medical affairs and commercial activities in the US & is expected to file an NDA with the US FDA at the end of 2022

Ref: Ionis | Image: AstraZeneca